The Temporo-spatial Dynamics of Genital Tract Microbiota

Sponsor
Peter Humaidan (Other)
Overall Status
Completed
CT.gov ID
NCT03363828
Collaborator
Statens Serum Institut (Other)
27
2
39.3
13.5
0.3

Study Details

Study Description

Brief Summary

The investigators aim to examine the endometrium with state of the art sequencing techniques to investigate the endometrial microbiota. The endometrial microbiota has been perceived to be sterile, however, this seems incorrect from recent studies. Thus, the primary outcome is to compare the rate of ascending infection from the semen to the vagina to the endometrium and to investigate which bacteria are capable of inhabiting these environments. Furthermore, cervical mucus will be obtained in order to test for immunological, microbiological and mechanical properties that may be involved in ascending infection. Finally, the study aim to characterize the temporal changes in the vaginal microbiota during estrogenic treatment with Estrofem® or Vivelle Dot (R) for preparation of the endometrium prior to embryo transfer.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
27 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in IVF-Freeze All Patients Treated With Estradiol
Actual Study Start Date :
Oct 1, 2017
Actual Primary Completion Date :
Sep 23, 2019
Actual Study Completion Date :
Jan 8, 2021

Arms and Interventions

Arm Intervention/Treatment
Normal microbiota

Based on qPCR and Next gen sequencing

Abnormal microbiota

Based on qPCR and Next gen sequencing

Drug: Estrofem
Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment

Outcome Measures

Primary Outcome Measures

  1. Rate of ascending infection/sharing of bacteria in the genital tract [This outcome data is measured at the day of oocyte retrieval.]

    Seminal, vaginal, cervical and endometrial samples will be compared at the time of oocyte retrieval.

Secondary Outcome Measures

  1. Next generation sequencing techniques will be used to assess the vaginal microbiota.I.e. measure of relative abundances [Examined longitudinally throughout the segmentation cycle. The estimated time to event is 40 days from oocyte retrieval until frozen embryo transfer following a strict protocol.]

    Vaginal microbiota changes throughout the preparation of the endometrium for frozen embryo transfer.

  2. qPCR to assess the vaginal microbiota. I.e. a quantitative measure Copies/mL. [Examined longitudinally throughout the segmentation cycle. The estimated time to event is 40 days from oocyte retrieval until frozen embryo transfer following a strict protocol.]

    Vaginal microbiota changes throughout the preparation of the endometrium for frozen embryo transfer.

  3. Number of participants with a Clinical pregnancy [7-9 weeks after inclusion.]

    Tested by clinical pregnancy scan by ultrasound in week 7-9

  4. Number of participants with a Live birth [36-42 weeks after inclusion]

    Tested by self-reported schemes

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients in IVF Freeze-all/segmentation treatment protocol.

  • Written informed consent.

Exclusion Criteria:
  • Uterine malformations

  • HIV, Hepatitis B or C positivity. HPV CIN 2 or higher. Chlamydia trachomatis positivity.

  • Any uncontrolled concomitant disease (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Fertility Clinic Skive Skive Denmark 7800
2 The Fertility Clinic, Regional Hospital of Skive Skive Denmark 7800

Sponsors and Collaborators

  • Peter Humaidan
  • Statens Serum Institut

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter Humaidan, Professor, Regionshospitalet Viborg, Skive
ClinicalTrials.gov Identifier:
NCT03363828
Other Study ID Numbers:
  • 1-10-72-345-15
First Posted:
Dec 6, 2017
Last Update Posted:
Feb 9, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2021